Can I Take Glycine With Sermorelin?

Sermorelin and glycine are different classes of compound

Sermorelin acetate is a synthetic peptide corresponding to the biologically active fragment of endogenous GHRH. It binds the GHRH receptor on pituitary somatotroph cells and stimulates the body's own pulsatile release of growth hormone (GH), rather than supplying GH directly. It is most often obtained as a compounded subcutaneous injection rather than as an FDA-approved product for adult GH stimulation; readers should confirm the regulatory and prescribing status of any specific product with their pharmacy or prescriber, since compounded peptide availability and formulation can change.

Glycine is the simplest amino acid. It is a normal component of the diet and of endogenous protein synthesis, and the body also makes it internally. As a supplement, it is most commonly used in the 3 g range at bedtime for sleep support, and it is also a structural component of collagen.

These are unrelated categories of substance: a prescription/compounded peptide drug and a dietary amino acid supplement. That distinction matters because their metabolism, monitoring needs, and regulatory oversight are not comparable.

Is there a documented interaction?

No published pharmacokinetic interaction between glycine and sermorelin was identified for this review. Mechanistically, this absence makes sense:

• Sermorelin is a peptide that is broken down in plasma and tissue by peptidases (enzymes that cleave peptide bonds), not metabolized through cytochrome P450 liver enzymes.
• Glycine is absorbed through amino acid transporters in the gut and metabolized mainly through the hepatic glycine cleavage system.

These pathways do not overlap, so there is no obvious mechanism for one compound to change the blood level of the other. That is a statement of biological plausibility based on how each compound is generally known to be handled by the body, not a citation to a study that tested the two together, because no such head-to-head study was located.

The more interesting question is pharmacodynamic: do the downstream effects of the two compounds interact even without a shared clearance pathway?

The sleep and growth hormone overlap

It is well established in sleep endocrinology that a large share of nightly GH secretion is tied to slow-wave sleep, particularly the first slow-wave episode of the night. This physiology is described in standard endocrinology references. See general background on the pituitary-GH axis in the NCBI Bookshelf endocrinology text.

Glycine is used as a sleep aid, and some published trials have reported that bedtime glycine improves subjective sleep quality and may shorten the time it takes to fall asleep. The specific trial data behind that claim need to be re-verified against the primary literature before being cited with exact numbers in a medical publication; the studies previously cited under this claim could not be confirmed as accurately represented and have been removed rather than repeated with unverified statistics.

If glycine does deepen or lengthen slow-wave sleep in a given individual, and if that person is also using sermorelin timed to the same sleep window, it is biologically plausible that the GH pulse triggered by sermorelin could be modestly larger on nights with better slow-wave sleep. This is a reasonable hypothesis built from two separate, generally accepted physiological facts. It has not been tested directly as a combination effect, and no clinical trial measuring IGF-1 or GH pulse amplitude with concurrent glycine and sermorelin use was identified. Readers should treat this as plausible, not proven.

Blood glucose

GH transiently reduces insulin sensitivity, and this is a recognized effect of GH and GH-secretagogue therapy generally. Some literature has explored whether glycine has an insulin-sensitizing effect at supplemental doses; the specific trial data on this point require primary-source verification and are not restated here with numbers that cannot currently be confirmed. Because both an insulin-desensitizing effect (from GH) and a possible glucose-related effect (from glycine) are plausible in the same person, anyone with prediabetes, type 2 diabetes, or other glucose-regulation concerns should discuss fasting glucose monitoring with their prescriber before combining sermorelin with any glycemically active supplement, glycine included.

Timing: what is reasonable, not what is prescribed

This article does not provide an individualized dosing recommendation. In general terms, sermorelin is typically administered by injection at bedtime to align with the nocturnal GH surge, and glycine, when used as a sleep aid, is typically taken shortly before bedtime as well. There is no evidence that simultaneous versus staggered timing changes the pharmacokinetics of either compound, since they are absorbed through entirely different routes (subcutaneous injection versus oral ingestion). Any specific dose or schedule should come from the clinician who prescribed the sermorelin, not from a general reference article.

Safety profile of glycine

Glycine is generally recognized as safe for use as a food ingredient, per its regulatory classification. This GRAS status reflects its safety as a food additive and does not itself constitute an evaluation of glycine as a therapeutic supplement combined with a peptide secretagogue, since that specific combination has not been the subject of FDA review.

People with significantly reduced kidney function may need to be more cautious with any added amino acid load, including supplemental glycine, because amino acids are nitrogenous compounds that the kidney must help clear. Anyone with chronic kidney disease should ask their nephrologist or prescriber before adding glycine at gram-level doses.

Who should be more cautious

People with diabetes or insulin resistance. Because GH transiently reduces insulin sensitivity and glycine may have glucose-related effects, fasting glucose monitoring is a reasonable precaution when starting or changing either compound.

People with active malignancy or a history of pituitary tumor. GH and IGF-1 signaling can support tumor growth, which is why GHRH-based therapy is generally avoided in active malignancy. This is a contraindication to sermorelin itself, independent of glycine; a compounding pharmacist or prescriber should be able to confirm current contraindication language for any specific sermorelin product.

People who are pregnant or breastfeeding. Sermorelin has not been established as safe in pregnancy or lactation. Dietary glycine intake from food is normal and expected, but supplemental glycine at gram doses has not been specifically studied in pregnancy. Both should be discussed with an obstetric provider rather than decided from a general article.

What is established, what is plausible, and what is not established

Established: Sermorelin and glycine are cleared through different, non-overlapping metabolic pathways, so a classic pharmacokinetic drug interaction (one compound raising or lowering blood levels of the other) is not mechanistically expected. GH release is concentrated during slow-wave sleep. Glycine is GRAS as a food ingredient.

Plausible but unproven: That glycine's sleep effects could modestly amplify the GH pulse sermorelin triggers, through the shared sleep-stage window, without this being a harmful interaction. That glycine's possible glucose effects could partially offset GH-related insulin resistance in some people.

Not established: Any specific change in IGF-1, GH pulse size, or glucose control from combining glycine with sermorelin in real patients. No clinical trial of the combination was identified. A quotation previously attributed to a 2019 growth hormone consensus statement could not be verified against a confirmed primary source in this review and has been removed rather than repeated; if this claim is needed for the final article, the specific guideline document should be pulled and re-cited directly by a reviewer with database access.

Evidence-status interaction assessment: glycine and sermorelin

Questions worth asking your prescriber or pharmacist

• What is the current formulation of my sermorelin, and does it already contain glycine as an excipient or stabilizer?
• Given my glucose history, should I check fasting glucose before and after starting glycine?
• Is there a reason to separate the timing of my sermorelin injection and glycine dose, or is bedtime co-administration fine for me specifically?
• What symptoms (for example, unusual headache, vision changes, or persistent high glucose readings) should prompt me to call before my next scheduled check-in?

When to seek prompt medical attention

Contact the prescribing clinician promptly for new or worsening headache, vision changes, joint swelling, or fasting glucose readings that are repeatedly elevated while on sermorelin. These are reasons to reassess the sermorelin regimen itself and are not specifically caused by glycine, but they should not be self-managed by adjusting supplement doses.